2 research outputs found
MicroRNAs and long non-coding RNAs in cartilage homeostasis and osteoarthritis
During the last decade, osteoarthritis (OA) has become one of the most prevalent musculoskeletal diseases worldwide. OA is characterized by progressive loss of articular cartilage, abnormal remodeling of subchondral bone, hyperplasia of synovial cells, and growth of osteophytes, which lead to chronic pain and disability. The pathological mechanisms underlying OA initiation and progression are still poorly understood. Non-coding RNAs (ncRNAs) constitute a large portion of the transcriptome that do not encode proteins but function in numerous biological processes. Cumulating evidence has revealed a strong association between the changes in expression levels of ncRNA and the disease progression of OA. Moreover, loss- and gain-of-function studies utilizing transgenic animal models have demonstrated that ncRNAs exert vital functions in regulating cartilage homeostasis, degeneration, and regeneration, and changes in ncRNA expression can promote or decelerate the progression of OA through distinct molecular mechanisms. Recent studies highlighted the potential of ncRNAs to serve as diagnostic biomarkers, prognostic indicators, and therapeutic targets for OA. MiRNAs and lncRNAs are two major classes of ncRNAs that have been the most widely studied in cartilage tissues. In this review, we focused on miRNAs and lncRNAs and provided a comprehensive understanding of their functional roles as well as molecular mechanisms in cartilage homeostasis and OA pathogenesis
Efficacy and safety of olmesartan medoxomilâamlodipine besylate tablet in Chinese patients with essential hypertension: A prospective, singleâarm, multiâcenter, realâworld study
Abstract There lacks realâworld study with a large sample size assessing olmesartan medoxomilâamlodipine besylate (OMâAML) tablet. Therefore, this study aimed to evaluate the efficacy and safety of OMâAML tablet in patients with essential hypertension. Totally, 1341 patients from 36 medical centers with essential hypertension who took OMâAML (20/5 mg) tablet were analyzed in the current prospective, singleâarm, multiâcenter, realâworld study (SVK study). Seated systolic blood pressure (SeSBP) and seated diastolic blood pressure (SeDBP) at baseline, week (W)4 and W8 were measured. The mean (±SE) change of SeSBP/SeDBP was â10.8 ± 0.4/â6.6 ± 0.3 mmHg at W4 and â12.7 ± 0.5/â7.6 ± 0.3 mmHg at W8, respectively. At W4, 78.8% and 29.0% patients achieved BP target by China and American Heart Association (AHA) criteria; at W8, 84.7% and 36.5% patients reached blood pressure (BP) target by China and AHA criteria, accordingly. Meanwhile, 80.2% and 86.4% patients achieved BP response at W4 and W8, respectively. Homeâmeasured SeSBP and SeDBP decreased from W1 to W8 (both p < .001). Besides, patientsâ and physiciansâ satisfaction were elevated at W8 compared with W0 (both p < .001). The medication possession rate was 94.8% from baseline to W4 and 91.3% from baseline to W8. The most common drugârelated adverse events were nervous system disorders (4.6%), vascular disorders (2.6%), and general disorders and administration site conditions (2.3%) by system organ class, which were generally mild and manageable. In conclusion, OMâAML tablet is one of the best antihypertensive agents in patients with essential hypertension